The effectiveness of chemotherapies and antimicrobials is frequently compromised by a cellular defense mechanism known as multidrug resistance (MDR). When therapeutic agents enter a resistant cancer cell or bacterium, they encounter active transmembrane proteins known as efflux pumps (such as P-glycoprotein or ABC transporters). Powered by ATP, these pumps act as cellular bouncers, capturing foreign molecules and expelling them before they can reach their intracellular targets.
To overcome this barrier, researchers are developing strategies to neutralize these molecular pumps. Rather than simply increasing drug dosages—which amplifies systemic toxicity—modern approaches focus on three intuitive mechanisms: jamming the pump's physical machinery, dismantling the cellular factories that produce them, or bypassing the pumps entirely using structural evasion.
Jamming the Gears: Functional Blockade
The most direct way to stop an efflux pump is to physically obstruct its transport mechanism. Small-molecule inhibitors can act as molecular wedges that bind to the pump, preventing it from changing shape to eject its cargo.
This can be achieved through competitive inhibition, where an adjuvant molecule saturates the pump's active site. As described by Lei Zhang et al. in Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells, certain small molecules occupy the primary drug-binding pocket of transporters like P-glycoprotein. This high-occupancy saturation leaves the pump unable to process the primary chemotherapeutic agent, effectively trapping the therapeutic payload inside the cell.
[Drug Molecule] --> [ Saturated Binding Pocket ] --> Pump Jammed (Drug Accumulates)
[Inhibitor] --> [ (e.g., Ribociclib / RN486) ]
To achieve a more robust blockade, therapies can target multiple binding sites simultaneously. Xing-Duo Dong et al. demonstrated this mechanism in Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells. The authors found that certain kinase inhibitors bind with high affinity to both the substrate-binding pocket and a distinct inhibitor-binding site on the transporter protein. This dual-site interaction locks the pump in an inactive conformation, preventing drug extrusion without requiring any changes to the cell's genetic expression.
Shutting Down the Factory: Downregulation
Instead of fighting individual pumps already stationed at the cell membrane, a more permanent solution is to stop the cell from manufacturing them. This strategy targets the upstream signaling pathways and transcription factors that trigger pump synthesis.
When a cell encounters stress or chemotherapy, survival pathways typically signal the nucleus to upregulate efflux pump production. By intercepting these signals, therapeutic agents can deplete the total number of functional pumps on the membrane over time. For instance, Wei Zhang et al. demonstrated in Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets that suppressing the NF-κB transcription factor prevents the activation of genes responsible for drug-efflux transporters.
[Upstream Signals (NF-κB / PI3K)] --| Blocked by Inhibitors --> [Gene Transcription] --> No New Efflux Pumps
This factory-level shutdown is effective across both oncology and microbiology. In bacterial models, Yuru Guo et al. showed in Luteolin increases susceptibility to macrolides by inhibiting MsrA efflux pump in Trueperella pyogenes that plant-derived flavonoids can downregulate efflux pump genes at the transcriptional level, reducing the physical density of defensive proteins on the cell wall. Furthermore, the regulatory networks governing these pumps can be highly specific; Lei Zhang et al. discovered in The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer that inhibiting specific PI3K subunits downregulates pump expression through a direct pathway that completely bypasses the well-known AKT signaling cascade.
Sneaking Past the Gatekeepers: Evasion and Sequestration
A third approach leaves the native pumps intact but alters how the drug interacts with the cell, ensuring the payload never encounters the efflux machinery.
One method is to encapsulate the drug within a protective nanocarrier. As explored by Yiming Li et al. in Natural Gastrointestinal Stable Pea Albumin Nanomicelles for Capsaicin Delivery and Their Effects for Enhanced Mucus Permeability at Small Intestine, shielding a hydrophobic drug inside the core of a nanomicelle prevents it from directly touching transmembrane efflux proteins during cellular entry. The entire package enters the cell via endocytosis, bypassing the surface-level pumps entirely.
Alternatively, researchers can engineer entirely new, passive pathways into the cell membrane that the pumps do not recognize. Yuan Li et al. achieved this in Ethane groups modified DNA nanopores to prolong the dwell time on live cell membranes for transmembrane transport by designing synthetic DNA nanopores. These artificial channels embed themselves into live cell membranes, creating a passive conduit for molecular entry that completely evades the substrate-recognition mechanisms of native protein pumps.
Option A: Nanocarrier Shielding Option B: Synthetic Nanopores
[ Nanomicelle Core ] [ Synthetic DNA Pore ]
[ (Shielded Drug) ] [ (Passive Entry) ]
↓ ↓
Bypasses Surface Pumps Evades Pump Recognition
Finally, if a drug cannot avoid the cytoplasm where efflux pumps operate, it can be routed to a secure intracellular compartment. As reviewed by Yue Yan et al. in Emerging magic bullet: subcellular organelle-targeted cancer therapy, targeting therapeutic payloads directly to specific organelles—such as the mitochondria or endoplasmic reticulum—sequesters the toxins away from cytoplasmic and membrane-bound efflux systems. By trapping the drug at its exact site of action, the cell's primary defense mechanism is rendered irrelevant.
Key Foundational Work
Adaptivity in Web-Based CALL (2002) — contributed 2 concept elements to this direction.
Overcoming Tumor Drug Resistance with High‐Affinity Taxanes: A SAR Study of C2‐Modified 7‐Acyl‐10‐Deacetyl Cephalomannines (2007) — contributed 2 concept elements to this direction.
Molecular biology of cantharidin in cancer cells (2007) — contributed 1 concept elements to this direction.